back to top
HomeTagsIIb

IIb

Roche's Part IIb Examine of Prasinezumab Missed Main Endpoint, However Suggests Potential Medical Profit in Early-Stage Parkinson's Illness By Investing.com

PADOVA research confirmed numerical delay in motor development and constructive developments on a number of secondary and exploratory endpointsPrasinezumab continues to be effectively tolerated...

Most Popular

spot_img